Clinical Trial Update: A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating veliparib (ABT-888), an oral PARP inhibitor, in combination with temozolomide in patients with metastatic prostate cancer; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Temozolomide (Temozolomide)
• Veliparib (veliparib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED